| Serial Number | 87366584 |
| Word Mark | EVSENA |
| Filing Date | Friday, March 10, 2017 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, October 26, 2020 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 25, 2017 |
| Goods and Services | Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
| Translation of Words in Mark | The word "EVSENA" has no meaning in a foreign language. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 16, 2017 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Allergan Sales, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Madison, NJ 07940 |
| Party Name | Allergan Sales, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Irvine, CA 92612 |
| Event Date | Event Description |
| Monday, October 26, 2020 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, October 26, 2020 | ABANDONMENT - NO USE STATEMENT FILED |
| Saturday, March 21, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, March 20, 2020 | EXTENSION 5 GRANTED |
| Friday, March 13, 2020 | EXTENSION 5 FILED |
| Friday, March 20, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, March 13, 2020 | TEAS EXTENSION RECEIVED |
| Wednesday, September 18, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, September 16, 2019 | EXTENSION 4 GRANTED |
| Monday, September 16, 2019 | EXTENSION 4 FILED |
| Monday, September 16, 2019 | TEAS EXTENSION RECEIVED |
| Tuesday, March 5, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, March 1, 2019 | EXTENSION 3 GRANTED |
| Friday, March 1, 2019 | EXTENSION 3 FILED |
| Friday, March 1, 2019 | TEAS EXTENSION RECEIVED |
| Tuesday, September 11, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, September 7, 2018 | EXTENSION 2 GRANTED |
| Friday, September 7, 2018 | EXTENSION 2 FILED |
| Friday, September 7, 2018 | TEAS EXTENSION RECEIVED |
| Thursday, February 1, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, January 30, 2018 | EXTENSION 1 GRANTED |
| Tuesday, January 30, 2018 | EXTENSION 1 FILED |
| Tuesday, January 30, 2018 | TEAS EXTENSION RECEIVED |
| Tuesday, September 19, 2017 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 25, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 25, 2017 | PUBLISHED FOR OPPOSITION |
| Wednesday, July 5, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, June 21, 2017 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Tuesday, June 20, 2017 | ASSIGNED TO LIE |
| Friday, May 12, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, May 12, 2017 | EXAMINER'S AMENDMENT ENTERED |
| Friday, May 12, 2017 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, May 12, 2017 | EXAMINERS AMENDMENT E-MAILED |
| Friday, May 12, 2017 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, May 9, 2017 | ASSIGNED TO EXAMINER |
| Thursday, March 16, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, March 14, 2017 | NEW APPLICATION ENTERED IN TRAM |